The IgA Nephropathy drugs market is set for 18.1% CAGR growth, led by biologics, FDA approvals, and major pharma R&D efforts ...

The global IgA nephropathy market is poised for substantial growth, with sales projected to increase from USD 46,821.7 million in 2025 to a remarkable USD 99,655.4 million by 2035. According to the ...

Clint McNeill and wife Sue share details about what it's like for him to have declining kidney function and how Sue does her best to slow it down.

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy ... of the autoimmune disease, also known as Berger’s disease, which occurs ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive than symptomatic treatments, offer substantial long-term cost benefits by ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

Crohn's disease is a chronic inflammatory bowel disease (IBD) that affects the digestive tract, often causing abdominal pain, persistent diarrhea, rectal bleeding, weight loss, and fatigue during ...

The acquisition would significantly boost Novartis’ position in rare kidney disease IgA nephropathy (IgAN), which the Swiss big pharma is targeting with oral complement factor B inhibitor ...

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday? Why Is Teva Stock Trading Higher On Tuesday? Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday? Why Is Teva Stock ...